{"id":"NCT02261467","sponsor":"Allergan","briefTitle":"A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides","officialTitle":"Evaluation of the Safety and Efficacy of Treatment With BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for Subjects With Forehead and Glabellar Facial Rhytides","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-10-21","primaryCompletion":"2015-06-04","completion":"2016-04-26","firstPosted":"2014-10-10","resultsPosted":"2017-06-23","lastUpdate":"2019-01-08"},"enrollment":421,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Forehead Rhytides","Glabellar Rhytides"],"interventions":[{"type":"BIOLOGICAL","name":"OnabotulinumtoxinA","otherNames":["BOTOX® Cosmetic","botulinum toxin Type A"]},{"type":"DRUG","name":"Normal Saline","otherNames":[]}],"arms":[{"label":"OnabotulinumtoxinA","type":"EXPERIMENTAL"},{"label":"Placebo followed by OnabotulinumtoxinA in Period 2","type":"PLACEBO_COMPARATOR"}],"summary":"This is a safety and efficacy study of onabotulinumtoxinA in subjects with forehead and glabellar facial rhytides (frown lines).","primaryOutcome":{"measure":"Percentage of Subjects With ≥2-Grade Improvement From Baseline on Both the Investigator's and Subject's Facial Wrinkle Scale (FWS) Ratings of Forehead Line Severity at Maximum Eyebrow Elevation","timeFrame":"Baseline, Day 30","effectByArm":[{"arm":"Placebo Followed by OnabotulinumtoxinA in Period 2","deltaMin":0,"sd":null},{"arm":"OnabotulinumtoxinA","deltaMin":61.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":8},"locations":{"siteCount":16,"countries":["United States","Canada","Ireland"]},"refs":{"pmids":["30096106"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":100},"commonTop":["Headache","Nasopharyngitis","Injection site bruising"]}}